Skip to main content
SpringerLink
Log in

α-Adrenoceptor antagonists best choice for initial treatment of lower urinary tract symptoms related to benign prostatic hyperplasia

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Santillo VM, Lowe FC. Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. Drugs Aging 2006; 23(10): 795–805

    Article  PubMed  CAS  Google Scholar 

  2. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 Sep; 132(3): 474–9

    PubMed  CAS  Google Scholar 

  3. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 Aug; 170 (2 Pt 1): 530–47

    Article  Google Scholar 

  4. AUA Practice Guidelines Committee. AUA Guideline on the Management of Benign Prostatic Hyperplasia (2003). Chapter 3: Results of the treatment outcomes analyses [online]. Available from URL: http://www.auanet.org [Accessed 2007 Mar 13]

  5. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 Jan; 28(1): 13–25

    Article  PubMed  Google Scholar 

  6. Lowe FC. Role of the newer alphal-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004 Nov; 26(11): 1701–13

    Article  PubMed  CAS  Google Scholar 

  7. Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 2000 Jun 25–28; Paris. Plymouth: Plymbridge Distributors Ltd, 2001: 425–57

    Google Scholar 

  8. Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 2006 Feb; 67(2): 225–31

    Article  PubMed  Google Scholar 

  9. British national formulary. No. 53. London: The Pharmaceutical Press, 2007 Mar

  10. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 Nov; 154(5): 1770–4

    Article  PubMed  CAS  Google Scholar 

  11. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349(25): 2387–98

    Article  PubMed  CAS  Google Scholar 

  12. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 Sep; 60(3): 434–41

    Article  PubMed  Google Scholar 

  13. Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation. Br J Urol 1992 Jul; 70(1): 65–72

    Article  PubMed  CAS  Google Scholar 

  14. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 Jan; 61(1): 119–26

    Article  PubMed  Google Scholar 

  15. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002 May; 41(5): 497–506

    Article  PubMed  CAS  Google Scholar 

  16. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006 Feb 9; 354(6): 557–66

    Article  PubMed  CAS  Google Scholar 

  17. Glemain P, Coulange C, Billebaud T, et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [in French]. Prog Urol 2002 Jun; 12(3): 395–403

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

α-Adrenoceptor antagonists best choice for initial treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Drugs Ther. Perspect 23, 9–11 (2007). https://doi.org/10.2165/00042310-200723060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723060-00003

Search

Navigation